福泰制药Vertex Pharmaceuticals Inc. (VRTX) 2018年10-K年度报告「NASDAQ」.pdf

1、UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON,D.C.20549_FORM 10-KxANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the Fiscal Year Ended December 31,2018oroTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the

2、 transition period from to Commission file number 000-19319_Vertex Pharmaceuticals Incorporated(Exact name of registrant as specified in its charter)Massachusetts04-3039129(State or other jurisdiction of incorporation or organization)(I.R.S.Employer Identification No.)50 Northern Avenue,Boston,Massa

3、chusetts02210(Address of principal executive offices)(Zip Code)Registrants telephone number,including area code(617)341-6100_Securities registered pursuant to Section 12(b)of the Exchange Act:Title of Each Class Name of Each Exchange on Which RegisteredCommon Stock,$0.01 Par Value Per Share The Nasd

4、aq Global Select MarketSecurities registered pursuant to Section 12(g)of the Exchange Act:None_Indicate by check mark if the registrant is a well-known seasoned issuer,as defined in Rule 405 of the Securities Act.Yes x No oIndicate by check mark if the registrant is not required to file reports purs

5、uant to Section 13 or Section 15(d)of the Exchange Act.Yes o No xIndicate by check mark whether the registrant:(1)has filed all reports required to be filed by Section 13 or 15(d)of the Securities Exchange Act of 1934 during thepreceding 12 months(or for such shorter period that the registrant was r

6、equired to file such reports),and(2)has been subject to such filing requirements for the past 90 days.Yes x No oIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T(232.405 of this chapt